> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lineage Buys Into Huntington’s Treatment With $4.7 Million Upfront And Milestones To Follow
- URL: https://www.bullished.co/lineage-buys-into-huntingtons-treatment-with-4-7-million-upfront-and-milestones-to-follow-c59877f6/
- Published: 2026-11-12T21:26:43.000Z
- Updated: 2026-11-12T21:26:43.000Z
- Description: The acquisition adds a third clinical-stage candidate, with sellers eligible for up to $48 million in development and regulatory milestones.
- Author: Matteo Parrino
- Tags: Deals, LCTX, Industry: Healthcare

Lineage Cell Therapeutics, which develops therapies to replace damaged or lost cells, [bought NeuroAirmid](https://www.sec.gov/Archives/edgar/data/0000876343/000119312526458377/lctx-20261112.htm?ref=bullished.co) Thursday, adding its third treatment candidate in human testing, according to an SEC filing. Investors in the Huntington’s disease therapy developer received [approximately $4.7 million](https://www.sec.gov/Archives/edgar/data/0000876343/000119312526458377/lctx-ex99%5F2.htm?ref=bullished.co) upfront, divided roughly equally between cash and Lineage shares.

## A Human Trial Already Underway

HUNT1, the acquired neural-cell transplant candidate, is being tested at the University of California, Irvine. Six patients have received treatment, with [no significant serious](https://www.sec.gov/Archives/edgar/data/0000876343/000119312526458377/lctx-ex99%5F1.htm?ref=bullished.co) adverse events reported, Lineage said in its earnings release Thursday.

The enrolling early-stage study plans to include up to 21 patients. It evaluates safety and tolerability, alongside exploratory measures of movement, cognition, behavior and biological markers of neuronal injury.

Huntington’s is an inherited disease that progressively damages neurons and impairs movement, thinking and behavior. Available treatments manage symptoms; there is no disease-modifying treatment or cure.

The program grew out of research led by Leslie M. Thompson, a University of California, Irvine professor and the study’s principal investigator. NeuroAirmid obtained its university technology license in 2024\. The California Institute for Regenerative Medicine, the state’s regenerative-medicine funding agency, supplied $16 million to help bring the program into clinical development and awarded up to $12 million for the ongoing trial.

## Milestones, Shares And Manufacturing Costs

Sellers can receive up to $5 million on the closing’s first anniversary and up to $48 million for development and regulatory milestones. Lineage also assumed [estimated clinical costs](https://www.sec.gov/Archives/edgar/data/0000876343/000119312526458377/lctx-ex99%5F2.htm?ref=bullished.co) of $3.1 million through February 2030.

The filing puts first-anniversary payments to sellers and payments covering NeuroAirmid obligations at up to $5.4 million. At closing, Lineage issued 2.2 million shares and paid $1.7 million to settle NeuroAirmid’s third-party obligations, alongside the investor consideration and a sellers’ expense fund.

Lineage may pay approximately half of subsequent seller payments in shares, subject to exchange limits. Qualifying future licensing or other strategic transactions can trigger further payments to sellers.

Lineage intends to move HUNT1 production onto AlloSCOPE, its cell-manufacturing platform. HUNT1 uses the same cell line as Lineage’s manufacturing technology and COR1 corneal therapy program.

Brian M. Culley, Lineage’s CEO, said “we believed our manufacturing expertise could [create significant additional](https://www.sec.gov/Archives/edgar/data/0000876343/000119312526458377/lctx-ex99%5F1.htm?ref=bullished.co) value for this program.” Lineage will handle future manufacturing and take over clinical development after the current study.

## Cash Runway Meets A Larger Pipeline

Lineage expects its September 30 cash, cash equivalents and marketable securities of $45.2 million to support planned operations into the second quarter of 2028.

Third-quarter revenue fell to approximately $1.5 million from $3.7 million a year earlier. Lineage attributed the decline primarily to fewer collaboration services for Roche and William Demant Invest, its hearing-loss research partner.

Operating expenses rose to approximately $8.8 million from $7.5 million. Research spending increased to $3.8 million from $3.3 million; administrative spending reached $4.9 million from $4.2 million.

The operating loss widened to $7.3 million from $3.8 million. Lineage reported net income of $4.2 million, primarily because of a non-cash warrant revaluation gain of $11.9 million. Warrants give investors rights to buy shares.

Its existing clinical programs include OPC1 for spinal cord injury and OpRegen for vision loss associated with advanced dry age-related macular degeneration. Roche and Genentech are developing OpRegen under a worldwide agreement, supported by a separate services agreement signed in May 2024.

Lineage expects initial animal-model results for COR1 in the first quarter of 2027\. It also plans to discuss ReSonance, its hearing-loss cell therapy, with the Danish Medicines Agency in the fourth quarter of 2026.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Lineage Cell Therapeutics, Inc. (LCTX)](https://www.sec.gov/Archives/edgar/data/0000876343/000119312526458377/lctx-20261112.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit lctx-ex99\_1.htm — Lineage Cell Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000876343/000119312526458377/lctx-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit lctx-ex99\_2.htm — Lineage Cell Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000876343/000119312526458377/lctx-ex99%5F2.htm?ref=bullished.co) — SEC EDGAR
- [Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.businesswire.com/news/home/20261112614737/en/Lineage-Cell-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Business-Update?ref=bullished.co) — businesswire.com
- [Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease](https://www.businesswire.com/news/home/20261112922275/en/Lineage-Announces-Acquisition-of-NeuroAirmid-Therapeutics-and-Clinical-Stage-Program-for-the-Treatment-of-Huntingtons-Disease?ref=bullished.co) — businesswire.com